Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609715 | 1.00 | HPGD (0.52) | HPGDKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL22337074 | 0.82 | HDAC3 (0.41) | HPGDKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL21609724 | 0.82 | HDAC3 (0.41) | HPGDKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL3290861 | 0.78 | NFE2L2 (0.37) | HPGDKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL6478831 | 0.77 | KMT2A (0.48) | HPGDKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL30674540 | 0.75 | NFE2L2 (0.70) | HPGDNFE2L2 | |
| SCHEMBL9808062 | 0.73 | TEAD1 (0.53) | HPGDKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL21622788 | 0.72 | MAOB (0.55) | KMT2AMEN1RAB9ANPC1CYP3A4 | |
| SCHEMBL21609730 | 0.71 | NFE2L2 (0.41) | HPGDKMT2AMEN1NFE2L2DRD2 | |
| SCHEMBL22336947 | 0.71 | RAB9A (0.38) | HPGDKMT2AMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519173-B2 | Process for the removal and return of a catalyst to a liquid phase medium | PHOSPHONICS LTD (GB) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519173-B2 | Process for the removal and return of a catalyst to a liquid phase medium | GRB2, GFRA2, LIFR | HPGD 3355/4885KMT2A 1913/4885MEN1 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.